Spirecut will partner with Sovereign Medical and Prof. Joanne Lord from the University of Southampton
Continue readingSpirecut recipient of the UK-Swiss Innovation Grant
Training with Sovereign Medical in London & Manchester
Spirecut & Sovereign Medical kicked off surgeons & radiologists trainings in London and Manchester on October 12th and 13th.
Continue readingSpirecut in Schweizer Illustrierte
A new minimally invasive procedure developed by Prof. Frédéric Schuind and his start-up Spirecut offers a quicker and less invasive solution. Using the Sono-Instruments®, specialists can operate under local anesthesia without making a surgical incision.
Continue readingSpirecut at Sachs Autumn Life Sciences Week
Spirecut attended the 10th HealthTech Investment Forum during Sachs Autumn Life Sciences Week in Basel on September 19th.
Continue readingSpirecut in Basler Zeitung
Spirecut, a Muttenz-based medtech start-up, is revolutionizing hand surgery with a groundbreaking ultrasound-guided technique spearheaded by CEO Frédéric Schuind. Moving away from traditional incision-based methods, Spirecut’s innovation requires a minor puncture to treat common hand disorders such as trigger finger and carpal tunnel syndrome.”
Continue readingSpirecut’s Training with KOLs
On Friday, June 23rd, Spirecut hosted a training session at Sitem-insel AG, located in Bern, Switzerland. The session primarily focused on the ultrasound-guided percutaneous surgical treatments of two prevalent hand conditions: trigger fingers and carpal tunnel syndrome. Participants included future Key Opinion Leaders (KOLs).
Continue readingSpirecut CEO Discusses Advances in Hand Surgery on X-Health.show Podcast
Prof Frédéric Schuind, Spirecut’s founder and CEO, recently participated in the X-Health.show podcast. The discussion centered around the latest breakthroughs in hand surgery, with a particular emphasis on trigger finger and carpal tunnel syndrome treatments.
Continue readingSpirecut’s European patent is officially approved
Spirecut’s European patent has been officially approved. This represents a significant milestone for our company as it reinforces our intellectual property portfolio. This development will enable us to expand our solutions across Europe, fostering innovation and enhancing healthcare in the region.
Continue readingSpirecut’s Successful Clinical Study with Archer Research
The study involved 30 adult participants, equally divided between the two conditions under investigation. One of the critical aspects of this research was the assessment of safety, gauged by the number of severe peri- and post-operative adverse events.
Continue readingSpirecut at Swiss Startup Days
We recently attended Startup Days (SUD), Switzerland’s premier startup conference, providing insights into our innovative solutions and opportunities for meaningful discussions and partnerships.
Continue reading